
primary studies - published RCT

Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis: Randomized, Controlled, Multicenter Trial.

Code: PM29688760

Year: 2018 **Date:** 2018

Author: Sagel SD

Study design (if review, criteria of inclusion for studies)

Multicenter, randomized, double-blind, controlled trial

Participants

73 pancreatic insufficient CF subjects 10 years of age and older with an FEV1 between 40-100% predicted

Interventions

Patients were randomized to 16 weeks of an antioxidant-enriched multivitamin or control multivitamin without antioxidant enrichment.

Outcome measures

Systemic antioxidant concentrations, markers of inflammation and oxidative stress, clinical outcomes (pulmonary exacerbations, anthropometric measures, pulmonary function), safety and tolerability.

Main results

Change in sputum myeloperoxidase concentration over 16 weeks, the primary efficacy endpoint, was not significantly different between the treated and control groups. Systemic antioxidant concentrations (beta-carotene, CoQ10, gamma-tocopherol, lutein) significantly increased in the antioxidant treated group (p

Authors' conclusions

Antioxidant supplementation was safe and well tolerated, resulting in increased systemic antioxidant concentrations and modest reductions in systemic inflammation after 4 weeks. Antioxidant treatment was also associated with a lower risk of first pulmonary exacerbation.

<http://dx.doi.org/10.1164/rccm.201801-0105OC>

See also

Am J Respir Crit Care Med. 2018 Apr 24. doi: 10.1164/rccm.201801-0105OC.

Keywords

Vitamin A; Vitamin D; Vitamin E; Vitamin K; Vitamins; pharmacological_intervention; Supplementation; Antioxidants;